Conference Coverage

PET-driven chemo strategy helps reduce toxicity in Hodgkin lymphoma

Publish date: July 6, 2018

 

REPORTING FROM ASCO 2018

SOURCE: Casasnovas O et al. ASCO 2018, Abstract 7503.

Pages

Recommended Reading

FDA approves new option in Hodgkin lymphoma treatment
MDedge Hematology and Oncology
Novel targeted cancer drugs cause fewer arrhythmias
MDedge Hematology and Oncology
Physical inactivity linked to lymphoma risk
MDedge Hematology and Oncology
Interim PET scans identify HL patients with better outcomes
MDedge Hematology and Oncology
Umbralisib has ‘distinct’ safety profile
MDedge Hematology and Oncology
‘Long-term benefits’ with nivolumab in cHL
MDedge Hematology and Oncology
CHMP recommends approval for generic carmustine
MDedge Hematology and Oncology
FDA places tazemetostat trials on partial hold
MDedge Hematology and Oncology
Art education benefits blood cancer patients
MDedge Hematology and Oncology
FDA approves BV plus chemo for untreated cHL
MDedge Hematology and Oncology